First Manhattan
NKTR icon

First Manhattan’s Nektar Therapeutics NKTR Stock Holding History

First Manhattan’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-33
Closed -$467 – 1086
2024
Q1 		$467 Hold
33
– – ﹤0.01% 1353
2023
Q4 		$282 Hold
33
– – ﹤0.01% 1383
2023
Q3 		$297 Hold
33
– – ﹤0.01% 1400
2023
Q2 		$287 Hold
33
– – ﹤0.01% 1380
2023
Q1 		$351 Hold
33
– – ﹤0.01% 1468
2022
Q4 		$1.13K Hold
33
– – ﹤0.01% 1575
2022
Q3 		$1K Hold
33
– – ﹤0.01% 1469
2022
Q2 		$1K Hold
33
– – ﹤0.01% 1492
2022
Q1 		$2K Hold
33
– – ﹤0.01% 1486
2021
Q4 		$6K Hold
33
– – ﹤0.01% 1355
2021
Q3 		$8K Hold
33
– – ﹤0.01% 1325
2021
Q2 		$8K Buy
+33
New +$9.13K ﹤0.01% 1315
2018
Q3 		– Sell
-40
Closed -$29K – 1427
2018
Q2 		$29K Hold
40
– – ﹤0.01% 1041
2018
Q1 		$63K Buy
+40
New +$51.5K ﹤0.01% 910

Other funds holding NKTR

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Manhattan's NKTR Position: Q2 2024 in Review

First Manhattan sold out of Nektar Therapeutics (NKTR) in Q2 2024, closing a stake of 33 shares — an estimated $467 sold.

First Manhattan first reported a position in NKTR in Q1 2018 and held it in 14 quarters. The position peaked at $63K in Q1 2018. 133 funds tracked by Wall St. Rank hold NKTR as of Q2 2024.

  • First Manhattan reported no remaining Nektar Therapeutics position as of Q2 2024 after selling out during the quarter.
  • First Manhattan sold 33 Nektar Therapeutics shares in Q2 2024, an estimated $467.
  • First Manhattan first reported a position in Nektar Therapeutics in Q1 2018 and held it in 14 quarters.
  • First Manhattan's Nektar Therapeutics position peaked at $63K in Q1 2018.
  • 133 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2024.

Based on First Manhattan's 13F filing for Q2 2024, filed 14 Aug 2024.